Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain

References

• Baron R, Brunnmüller U, Brasser M, May M, Binder A. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: open-label, non-comparative, flexible-dose study. Eur J Pain. 2008;12:850–58.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573–81.
   PubMed Web of Science ®Google Scholar
• Jääskeläinen SK. Pregabalin for painful neuropathy. Lancet Neurol. 2005;4:207–8.
   PubMed Web of Science ®Google Scholar
• Vinik A. CLINICAL REVIEW: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab. 2005;90:4936–45.
   PubMed Web of Science ®Google Scholar
• Xochilcal-Morales M, Castro EM, Guajardo-Rosas J, Obregón TN, Acevedo JC, Chucan JM, et al.. A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America. Int J Clin Pract. 2010;64(9):1301–9.
   PubMed Web of Science ®Google Scholar
• Moon DE, Lee DI, Lee SC, Song SO, Yoon DM, Yoon MH, et al.. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010;32:2370–85.
   PubMed Web of Science ®Google Scholar
• Baron R, Freynhagen R, Tölle TR, Cloutier C, Leon T, Murphy TK, et al.. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain. 2010;150:420–7.
   PubMed Web of Science ®Google Scholar
• Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs. 2007;67:569–85.
   PubMed Web of Science ®Google Scholar
• Davis MP. What is new in neuropathic pain? Support Care Cancer. 2007;15:363–72.
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Takasu K, Ono H, Tanabe M. Pregabalin, S-(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology. 2007;53(7):842–53.
   PubMed Web of Science ®Google Scholar
• Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem. 2009;9:71–8.
   PubMedGoogle Scholar
• Pluijms W, Huygen F, Cheng J, Mekhail N, van Kleef M, Van Zundert J, et al.. Evidence-based interventional pain medicine according to clinical diagnoses. 18. Painful diabetic polyneuropathy. Pain Pract. 2011;11:191–8.
   PubMed Web of Science ®Google Scholar
• Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, et al.. Evidence-based guideline: treatment of painful diabetic neuropathy – report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation. Muscle Nerve. 2011;43:910–7.
   PubMed Web of Science ®Google Scholar
• Bril V. Treatments for diabetic neuropathy. J Peripher Nerv Syst. 2012;17(Suppl 2):22–7.
   PubMed Web of Science ®Google Scholar
• Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, et al.. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28:109–16.
   PubMed Web of Science ®Google Scholar
• Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev. 2008;24(Suppl 1):S52–7.
   PubMed Web of Science ®Google Scholar
• Zilliox L, Russell JW. Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol. 2011;13:143–59.
   PubMed Web of Science ®Google Scholar
• Rizzato B, Leone G, Misaggi G, Zivi I, Diomedi M. Efficacy and tolerability of pregabalin versus topiramate in the prophylaxis of chronic daily headache with analgesic overuse: an open-label prospective study. Clin Neuropharmacol. 2011;34:74–8.
   PubMed Web of Science ®Google Scholar
• Zareba G. New treatment options in the management of fibromyalgia: role of pregabalin. Neuropsychiatr Dis Treat. 2008;4:1193–201.
   PubMedGoogle Scholar
• Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm. 2007;64:1475–82.
   PubMed Web of Science ®Google Scholar
• Tomson T, Almas M, Giordano S, Cabrera J. The impact of background antiepileptic drugs on the efficacy and safety of pregabalin in treating partial-onset seizures: a post hoc analysis of combined clinical trials. Epilepsy Res. 2011;96:64–73.
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al.. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113–e88.
   PubMed Web of Science ®Google Scholar
• Baidya DK, Agarwal A, Khanna P, Arora MK. Pregabalin in acute and chronic pain. J Anaesthesiol Clin Pharmacol. 2011;27:307–14.
   PubMedGoogle Scholar
• Kim JS, Bashford G, Murphy TK, Martin A, Dror V, Cheung R. Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain. 2011;152:1018–23.
   PubMed Web of Science ®Google Scholar
• Mittal M, Pasnoor M, Mummaneni RB, Khan S, McVey A, Saperstein D, et al.. Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy. Int J Neurosci. 2011;121:521–7.
   PubMed Web of Science ®Google Scholar
• Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs. 2012;21:1019–29.
   PubMed Web of Science ®Google Scholar
• Park JM, Jwa SW, Song M, Kim HS, Ko HC, Kim MB, et al.. Efficacy and safety of pregabalin for the treatment of chronic pruritus in Korea. J Dermatol. 2012;39:790–1.
   PubMed Web of Science ®Google Scholar
• Solak Y, Biyik Z, Atalay H, Gaipov A, Guney F, Turk S, et al.. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance hemodialysis patients: a prospective crossover study. Nephrology (Carlton) 2012;17(8):710–7.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137–50.
   PubMed Web of Science ®Google Scholar
• Vorobeychik Y, Gordin V, Mao J, Chen L. Combination therapy for neuropathic pain: a review of current evidence. CNS Drugs. 2011;25:1023–34.
   PubMed Web of Science ®Google Scholar
• Vondracek P, Oslejskova H, Kepak T, Mazanek P, Sterba J, Rysava M, et al.. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol. 2009;13:332–6.
   PubMed Web of Science ®Google Scholar
• Rahman W, Bauer CS, Bannister K, Vonsy JL, Dolphin AC, Dickenson AH. Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain. Mol Pain. 2009;5:45.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP, Sharma U, LaMoreaux L, Bockbrader H, et al.. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274–83.
   PubMed Web of Science ®Google Scholar
• Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother. 2006;6:1629–35.
   PubMedGoogle Scholar
• Tentolouris NK. Painful diabetic neuropathy-new choice of first-line therapy? Nat Rev Endocrinol. 2011;7:381–3.
   PubMed Web of Science ®Google Scholar
• Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203–13.
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Florek-Luszczki M. Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212-2 mesylate in the hot-plate test in mice: an isobolographic analysis. Pharmacol Rep. 2012;64(3):723–32.
   PubMed Web of Science ®Google Scholar
• Hurley RW, Chatterjea D, Rose Feng M, Taylor CP, Hammond DL. Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology. 2002;97(5):1263–73.
   PubMed Web of Science ®Google Scholar
• Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs. 2007;67:1265–89.
   PubMed Web of Science ®Google Scholar
• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31:1448–54.
   PubMed Web of Science ®Google Scholar
• Anastassiou E, Iatrou CA, Vlaikidis N, Vafiadou M, Stamatiou G, Plesia E, et al.. ATLAS investigators. Impact of pregabalin treatment on pain, pain-elated sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Investig. 2011;31:417–26.
   PubMed Web of Science ®Google Scholar
• Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Emir B, Murphy TK, Zeiher BG, Pauer L, Scott G, et al.. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin Ther. 2012;34:1092–102.
   PubMed Web of Science ®Google Scholar
• Criswell KA, Cook JC, Morse D, Lawton M, Somps C, Obert L, et al.. Pregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice, a process inhibited by dietary vitamin E supplementation. Toxicol Sci. 2012;128:42–56.
   PubMed Web of Science ®Google Scholar
• Forde G. Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles. J Fam Pract. 2007;56:3–12.
   PubMed Web of Science ®Google Scholar
• Frampton JE, Scott LJ. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs. 2004;64:2813–20.
   PubMed Web of Science ®Google Scholar
• Guay DR. Pregabalin in neuropathic pain: a more ‘pharmaceutically elegant’ gabapentin? Am J Geriatr Pharmacother. 2005;3:274–87.
   PubMedGoogle Scholar
• Masa-Vázquez LA, Villamil-Cajoto I, Villar Del Castillo A. Efficacy and safety of pregabalin in neuropathic pain treatment: a still unreported adverse effect. Minerva Med. 2008;99:533–4.
   PubMedGoogle Scholar
• Toth C. Drug safety evaluation of pregabalin. Expert Opin Drug Saf. 2012;11(3):487–502.
   PubMed Web of Science ®Google Scholar
• Tanabe M, Murakami T, Ono H. Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy. J Pharmacol Sci. 2008;107(2):213–20.
   PubMed Web of Science ®Google Scholar
• Eddy N, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl - and dithienylbutylamines. J Pharmacol Exp Ther. 1953;107:385–93.
   PubMed Web of Science ®Google Scholar
• Talarek S, Orzelska J, Listos J, Fidecka S. Effects of sildenafil treatment on the development of tolerance to diazepam-induced motor impairment and sedation in mice. Pharmacol Rep. 2010;62(4):627–34.
   PubMed Web of Science ®Google Scholar
• Schlesier K, Harwat M, Böhm V, Bitsch R. Assessment of antioxidant activity by using different in vitro methods. Free Rad Res. 2002;36(2):177–87.
   PubMed Web of Science ®Google Scholar
• Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine. Pain Pract. 2012;12:209–18.
   PubMed Web of Science ®Google Scholar
• Gore M, Zlateva G, Tai KS, Chandran AB, Leslie D. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care. Pain Pract. 2011;11:167–79.
   PubMed Web of Science ®Google Scholar
• Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician. 2010;82:151–8.
   PubMed Web of Science ®Google Scholar
• Naylor HK, Raymond CB. Treatment of neuropathic pain in patients with chronic kidney disease. CANNT J. 2011;21:34–8.
   PubMedGoogle Scholar
• Tanenberg RJ, Irving GA, Risser RC, Ahl J, Robinson MJ, Skljarevski V, et al.. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc. 2011;86:615–26.
   PubMed Web of Science ®Google Scholar
• Martinez JA, Kasamatsu M, Rosales-Hernandez A, Hanson LR, Frey WH, Toth CC. Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states. Mol Pain. 2012;8:3.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628–38.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8–14.
   PubMed Web of Science ®Google Scholar
• Kuritzky L. Managing diabetic peripheral neuropathic pain in primary care. J Fam Pract. 2010;59:S15–22.
   PubMed Web of Science ®Google Scholar
• Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab. 2008;10:99–108.
   PubMed Web of Science ®Google Scholar
• Robinson-Papp J, Simpson DM. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain Med. 2007;8(Suppl 2):S43–49.
   PubMedGoogle Scholar
• Pal P, Kanaujiya JK, Lochab S, Tripathi SB, Sanyal S, Behre G, et al.. Proteomic analysis of rosiglitazone and guggulsterone treated 3T3-L1 preadipocytes. Mol Cell Biochem. 2013;376(1–2):81–93.
   PubMed Web of Science ®Google Scholar
• Li YY, Wu HS, Tang L, Feng CR, Yu JH, Li Y, et al.. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo. Pharmacol Res. 2007;56(4):335–43.
   PubMed Web of Science ®Google Scholar
• Takazawa T, Yamauchi T, Tsuchida A, Takata M, Hada Y, Iwabu M, et al.. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes. J Biol Chem. 2009;284(44):30049–57.
   PubMed Web of Science ®Google Scholar
• Janaszewska A, Bartosz G. Assay of total antioxidant capacity: comparison of four methods as applied to human blood plasma. Scand J Clin Lab Invest. 2002;62:231–6.
   PubMed Web of Science ®Google Scholar